Fig. 1: Transcriptional landscape of human AML at single-cell resolution.
From: Longitudinal single-cell profiling of chemotherapy response in acute myeloid leukemia
A Swimmer plots detailing the patients’ clinical course and timepoints selected for scRNAseq (red diamonds). Top horizontal axis: days from diagnosis. CR1, first complete remission. Rel1/2, first/second relapse; EM Rel, extramedullary relapse; NR, no response; MLFS, morphologic leukemia-free state; FLA-Ida, Fludarabine 50 mg/m2 D1-5, Cytarabine 1000 mg/m2 q12h D1-5, Idarubicin 10 mg/m2 D1-3, FLAG-Ida, as before, with granulocyte colony stimulating factor 30MU D0-5; 3 + 7, Cytarabine 100–200 mg/m2 D1-7 and Daunorubicin 60 mg/m2 D1-3; ICE, Idarubicin 12 mg/m2 D1-3, Cytarabine 100 mg/m2 D1-7, Etoposide 100 mg/m2 D1-5; MAMAC(3)5; m-Amsacrine 100 mg/m2 D1-(3)5, Cytarabine 1000 mg/m2 q12h D1-(3)5; A: Cytarabine monotherapy, with the number indicating the cumulative dose in g/m2 (e.g. A16, Cytarabine 16 g/m2); HMA: hypomethylating agent; HSCT I/II, first/second allogeneic hematopoietic stem cell transplantation; ASCT, autologous stem cell transplantation. B All single-cell RNA sequencing plots are based on uniform manifold approximation and projection (UMAP) embeddings; x-axis: UMAP_1, y-axis UMAP_2. UMAP plot of NPM1mut AML cells colored by unsupervised clustering (resolution 0.6) and labeled according to annotated cell phenotypes. n = 42,398 cells. C UMAP density plots of each patient’s AML blasts at diagnosis within the NPM1mutAML landscape. Cells are colored according to the patient’s treatment response: dark red for primary refractory, orange for relapse after CR, green for persistent CR. D Pseudotime trajectory (black lines) and pseudotime (color gradient) for AML cells at diagnosis projected on UMAP embedding. Trajectory root is set from the centroid of CD34 transcript expressing cells (white dot). E Left: UMAP plot of del(7) AML cells colored by unsupervised clustering (resolution 0.6) and labeled according to annotated cell phenotypes. Right: UMAP density plots displaying the distribution of each patient’s AML cells at diagnosis within the del(7) AML landscape. Cells are colored according to the patient’s treatment response: dark red for primary refractory and orange for relapse after CR. n = 33,308 cells.
